The role of erythropoietin and its receptor in growth, survival and therapeutic response of human tumor cells. From clinic to bench - a critical review.

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1806, Issue 1, 2010, Pages 82-95

  Szenajch, Jolanta ^a   Wcislo, Gabriel ^a   Jeong, Jee Yeong ^b,d   Szczylik, Cezary ^a   Feldman, Laurie ^c,d  

^a MILITARY INSTITUTE OF MEDICINE   (Poland)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cancer; Drug resistance; Erythropoietin; Erythropoietin receptor; Radioresistance; Signaling

Indexed keywords

CARBOPLATIN; CISPLATIN; DACARBAZINE; DAUNORUBICIN; DOXORUBICIN; ERYTHROPOIETIN RECEPTOR; ESTROGEN RECEPTOR; HYPERICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PLATINUM COMPLEX; PROTEIN BCL 2; PROTEIN KINASE C; RECOMBINANT ERYTHROPOIETIN; STAT3 PROTEIN; STAT5 PROTEIN; TAMOXIFEN; VINBLASTINE;

ANEMIA; AUTOCRINE EFFECT; BLOOD TRANSFUSION; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELL GROWTH; CELL SURVIVAL; CHEMOSENSITIVITY; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPOXIA; IONIZING RADIATION; MALIGNANT TRANSFORMATION; NONHUMAN; OVERALL SURVIVAL; PARACRINE SIGNALING; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR VASCULARIZATION;

ANIMALS; CELL PROLIFERATION; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; ERYTHROPOIETIN; HUMANS; NEOPLASMS; RECEPTORS, ERYTHROPOIETIN; SIGNAL TRANSDUCTION;

EID: 77953691205     PISSN: 0304419X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbcan.2010.04.002     Document Type: Review

References (144)

1. Krantz S.B. Pathogenesis and treatment of the anemia of chronic disease. Am. J. Med. Sci. 1994, 307:353-359.
2. Steinberg D. Anemia and cancer. CA-A Cancer J. Clinic. 1989, 39:296-304.
3. Fisher J.W. Erythropoietin: physiology and pharmacology update. Exp. Biol. Med. (Maywood) 2003, 228:1-14.
4. Jacobs K., Shoemaker C., Rudersdorf R., Neill S.D., Kaufman R.J., Mufson A., Seehra J., Jones S.S., Hewick R., Fritsch E.F. Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature 1985, 313:806-810.
5. Lin F.K., Suggs S., Lin C.H., Browne J.K., Smalling R., Egrie J.C., Chen K.K., Fox G.M., Martin F., Stabinsky Z. Cloning and expression of the human erythropoietin gene. Proc. Natl. Acad. Sci. U. S. A. 1985, 82:7580-7584.
6. Sytkowski A.J. Erythropoietin: blood, brain and beyond 2004, Wiley-VCH, Weinheim. first ed.
7. Glaspy J., Bukowski R., Steinberg D., Taylor C., Tchekmedyian S., Vadhan-Raj S. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J. Clin. Oncol. 1997, 15:1218-1234.
8. Cella D., Zagari M.J., Vandoros C., Gagnon D.D., Hurtz H., Nortier J.W.R. Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population. J. Clin. Oncol. 2003, 21:366-373.
9. Leyland-Jones B. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol. 2003, 4:459-460.
10. Henke M., Laszig R., Rübe C., Schäfer U., Haase K., Schilcher B., Mose S., Beer K.T., Burger U., Dougherty C., Frommhold H. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003, 362:1255-1260.
11. Henke M., Mattern D., Pepe M., Bézay C., Weissenberger C., Werner M., Pajonk F. Do erythropoietin receptors on cancer cells explain unexpected clinical findings?. J. Clin. Oncol. 2006, 24:4708-4713.
12. Elliott S., Busse L., Bass M.B., Lu H., Sarosi I., Sinclair A.M., Spahr C., Um M., Van G., Begley C.G. Anti-Epo receptor antibodies do not predict Epo receptor expression. Blood 2006, 107:1892-1895.
13. Jelkmann W., Bohlius J., Hallek M., Sytkowski A.J. The erythropoietin receptor in normal and cancer tissues. Crit. Rev. Oncol. Hematol. 2008, 67:39-61.
14. Bohlius J., Wilson J., Seidenfeld J., Piper M., Schwarzer G., Sandercock J., Trelle S., Weingart O., Bayliss S., Djulbegovic B., Bennett C.L., Langensiepen S., Hyde C., Engert A. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J. Natl. Cancer Inst. 2006, 98:708-714.
15. Bohlius J., Schmidlin K., Brillant C., Schwarzer G., Trelle S., Seidenfeld J., Zwahlen M., Clarke M., Weingart O., Kluge S., Piper M., Rades D., Steensma D.P., Djulbegovic B., Fey M.F., Ray-Coquard I., Machtay M., Moebus V., Thomas G., Untch M., Schumacher M., Egger M., Engert A. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 2009, 373:1532-1542.
16. Bennett C.L., Silver S.M., Djulbegovic B., Samaras A.T., Blau C.A., Gleason K.J., Barnato S.E., Elverman K.M., Courtney D.M., McKoy J.M., Edwards B.J., Tigue C.C., Raisch D.W., Yarnold P.R., Dorr D.A., Kuzel T.M., Tallman M.S., Trifilio S.M., West D.P., Lai S.Y., Henke M. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008, 299:914-924.
17. Glaspy J.A. Erythropoietin in cancer patients. Annu. Rev. Med. 2009, 60:181-192.
18. Leyland-Jones B., Semiglazov V., Pawlicki M., Pienkowski T., Tjulandin S., Manikhas G., Makhson A., Roth A., Dodwell D., Baselga J., Biakhov M., Valuckas K., Voznyi E., Liu X., Vercammen E. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J. Clin. Oncol. 2005, 23:5960-5972.
19. Temkin S.M., Hellmann M., Serur E., Lee Y., Abulafia O. Erythropoietin administration during primary treatment for locally advanced cervical carcinoma is associated with poor response to radiation. Int. J. Gynecol. Cancer 2006, 16:1855-1861.
20. (last access 30 March 2010) Amgen Announces Interim Results Of Aranesp(R) "PREPARE" Study In Breast Cancer Patients, (03 Dec 2007). http://www.ncbi.nlm.nih.gov/pubmed/19762512.
21. Overgaard J., Hoff C., Hansen H.S., Specht L., Overgaard M., Grau C., Andersen E., Johansen J., Andersen L., Evensen J. Randomized study of the importance of Novel Erythropoiesis Stimulating Protein (Aranesp) for the effect of radiotherapy in patients with primary squamous cell carcinoma of the hed and neck (HNSCC) - the Danish Head and Neck Group DAHANCA 10 randomized trial. Eur. J. Cancer Suppl. 2007, 5:7.
22. Wright J.R., Ung Y.C., Julian J.A., Pritchard K.I., Whelan T.J., Smith C., Szechtman B., Roa W., Mulroy L., Rudinskas L., Gagnon B., Okawara G.S., Levine M.N. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J. Clin. Oncol. 2007, 25:1027-1032.
23. Smith R.E., Aapro M.S., Ludwig H., Pintér T., Smakal M., Ciuleanu T.E., Chen L., Lillie T., Glaspy J.A. Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J. Clin. Oncol. 2008, 26:1040-1050.
24. Thomas G., Ali S., Hoebers F.J.P., Darcy K.M., Rodgers W.H., Patel M., Abulafia O., Lucci J.A., Begg A.C. Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0g/dL with erythropoietin vs above 10.0g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer. Gynecol. Oncol. 2008, 108:317-325.
25. Antonadou D., Cardamakis E., Puglisi M., Malamos N., Throuvalas N. Erythropoietin enhances radiation treatment efficacy in patients with pelvic malignancies. Final results of randomized phase III study. Eur. J. Cancer 2001, 37(Suppl 6):S144.
26. Littlewood T.J., Bajetta E., Nortier J.W., Vercammen E., Rapoport B. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J. Clin. Oncol. 2001, 19:2865-2874.
27. Blohmer J., Wurschmidt F., Petry U., Weise G., Sehouli J., Kimming R., Dressler P., Kentenich H., Kohls A. Results with sequential adjuvant chemo-radiotherapy with vs without epoetin alfa for patients with high-risk cervical cancer: results of a prospective, randomized, open and controlled AGO-and NOGGO-intergroup study. Ann. Oncol. 2004, 15(Suppl 3):iii128.
28. Vansteenkiste J., Pirker R., Massuti B., Barata F., Font A., Fiegl M., Siena S., Gateley J., Tomita D., Colowick A.B., Musil J. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J. Natl. Cancer Inst. 2002, 94:1211-1220.
29. Chang J., Couture F., Young S., McWatters K., Lau C.Y. Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. J. Clin. Oncol. 2005, 23:2597-2605.
30. Grote T., Yeilding A.L., Castillo R., Butler D., Fishkin E., Henry D.H., DeLeo M., Fink K., Sullivan D.J. Efficacy and safety analysis of epoetin alfa in patients with small-cell lung cancer: a randomized, double-blind, placebo-controlled trial. J. Clin. Oncol. 2005, 23:9377-9386.
31. Savonije J.H., van Groeningen C.J., van Bochove A., Honkoop A.H., van Felius C.L., Wormhoudt L.W., Giaccone G. Effects of early intervention with epoetin alfa on transfusion requirement, hemoglobin level and survival during platinum-based chemotherapy: results of a multicenter randomised controlled trial. Eur. J. Cancer 2005, 41:1560-1569.
32. Witzig T.E., Silberstein P.T., Loprinzi C.L., Sloan J.A., Novotny P.J., Mailliard J.A., Rowland K.M., Alberts S.R., Krook J.E., Levitt R., Morton R.F. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J. Clin. Oncol. 2005, 23:2606-2617.
33. Machtay M., Pajak T.F., Suntharalingam M., Shenouda G., Hershock D., Stripp D.C., Cmelak A.J., Schulsinger A., Fu K.K. Radiotherapy with or without erythropoietin for anemic patients with head and neck cancer: a randomized trial of the Radiation Therapy Oncology Group (RTOG 99-03). Int. J. Radiat. Oncol. Biol. Phys. 2007, 69:1008-1017.
34. Moebus V., Lueck H., Thomssen C., Harbeck N., Nitz U., Kreienberg R., Jackisch C., Schneeweiss A., Huober J., du Bois A., Untch M. The impact of epoetin-alpha on anemia, red blood cell (RBC) transfusions, and survival in breast cancer patients (pts) treated with dose-dense sequential chemotherapy: mature results of an AGO phase III study (ETC trial). J. Clin. Oncol. 2007, 25(18S):569.
35. Aapro M., Leonard R.C., Barnadas A., Marangolo M., Untch M., Malamos N., Mayordomo J., Reichert D., Pedrini J.L., Ukarma L., Scherhag A., Burger H. Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study. J. Clin. Oncol. 2008, 26:592-598.
36. Pirker R., Ramlau R.A., Schuette W., Zatloukal P., Ferreira I., Lillie T., Vansteenkiste J.F. Safety and efficacy of darbepoetin alpha in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide. J. Clin. Oncol. 2008, 26:2342-2349.
37. Glaspy J., Crawford J., Vansteenkiste J., Henry D., Rao S., Bowers P., Berlin J.A., Tomita D., Bridges K., Ludwig H. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br. J. Cancer 2010, 102:301-315.
38. Rizzo J.D., Somerfield M.R., Hagerty K.L., Seidenfeld J., Bohlius J., Bennett C.L., Cella D.F., Djulbegovic B., Goode M.J., Jakubowski A.A., Rarick M.U., Regan D.H., Lichtin A.E. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J. Clin. Oncol. 2008, 26:132-149.
39. Greil R., Thödtman R., Roila F. Erythropoietins in cancer patients: ESMO recommendations for use. Ann. Oncol. 2008, 19(Suppl 2):ii113-ii115.
40. The Lancet Oncology Erythropoietin analogues: an unnecessary class of drugs. Lancet Oncol. 2008, 9:81.
41. (last access 30 March 2010) Information on Erythropoiesis-Stimulating Agents (ESA) Epoetin alfa (marketed as Procrit, Epogen) Darbepoetin alfa (marketed as Aranesp), (16 Feb 2010). http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm109375.htm.
42. Juneja V., Keegan P., Gootenberg J.E., Rothmann M.D., Shen Y.L., Lee K.Y., Weiss K.D., Pazdur R. Continuing reassessment of the risks of erythropoiesis-stimulating agents in patients with cancer. Clin. Cancer Res. 2008, 14:3242-3247.
43. Ray-Coquard I., Dussart S., Goillot C., Mayeur D., Debourdeau P., Ghesquieres H., Bachelot T., Le Cesne A., Anglaret B., Agostini C., Guastalla J., Lancry L., Biron P., Desseigne F., Blay J. A risk model for severe anemia to select cancer patients for primary prophylaxis with epoetin alpha: a prospective randomized controlled trial of the ELYPSE study group. Ann. Oncol. 2009, 20:1105-1112.
44. Harrison L., Blackwell K. Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy?. Oncologist 2004, 9(Suppl 5):31-40.
45. Sinclair A.M., Coxon A., McCaffery I., Kaufman S., Paweletz K., Liu L., Busse L., Swift S., Elliott S., Begley C.G. Functional erythropoietin receptor is undetectable in endothelial, cardiac, neuronal, and renal cells. Blood 2010, Electronic publication ahead of print.
46. Suzuki N., Ohneda O., Takahashi S., Higuchi M., Mukai H.Y., Nakahata T., Imagawa S., Yamamoto M. Erythroid-specific expression of the erythropoietin receptor rescued its null mutant mice from lethality. Blood 2002, 100:2279-2288.
47. Yasuda Y., Fujita Y., Matsuo T., Koinuma S., Hara S., Tazaki A., Onozaki M., Hashimoto M., Musha T., Ogawa K., Fujita H., Nakamura Y., Shiozaki H., Utsumi H. Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis 2003, 24:1021-1029.
48. Papworth K., Bergh A., Grankvist K., Ljungberg B., Rasmuson T. Expression of erythropoietin and its receptor in human renal cell carcinoma. Tumour Biol. 2009, 30:86-92.
49. Yasuda Y., Fujita Y., Masuda S., Musha T., Ueda K., Tanaka H., Fujita H., Matsuo T., Nagao M., Sasaki R., Nakamura Y. Erythropoietin is involved in growth and angiogenesis in malignant tumours of female reproductive organs. Carcinogenesis 2002, 23:1797-1805.
50. Kumar S.M., Acs G., Fang D., Herlyn M., Elder D.E., Xu X. Functional erythropoietin autocrine loop in melanoma. Am. J. Pathol. 2005, 166:823-830.
51. Acs G., Zhang P.J., Rebbeck T.R., Acs P., Verma A. Immunohistochemical expression of erythropoietin and erythropoietin receptor in breast carcinoma. Cancer 2002, 95:969-981.
52. Westenfelder C., Baranowski R.L. Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney Int. 2000, 58:647-657.
53. Feldman L., Wang Y., Rhim J.S., Bhattacharya N., Loda M., Sytkowski A.J. Erythropoietin stimulates growth and STAT5 phosphorylation in human prostate epithelial and prostate cancer cells. Prostate 2006, 66:135-145.
54. Acs G., Acs P., Beckwith S.M., Pitts R.L., Clements E., Wong K., Verma A. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res. 2001, 61:3561-3565.
55. Carvalho G., Lefaucheur C., Cherbonnier C., Métivier D., Chapel A., Pallardy M., Bourgeade M., Charpentier B., Hirsch F., Kroemer G. Chemosensitization by erythropoietin through inhibition of the NF-kappaB rescue pathway. Oncogene 2005, 24:737-745.
56. Solar P., Feldman L., Jeong J., Busingye J.R., Sytkowski A.J. Erythropoietin treatment of human ovarian cancer cells results in enhanced signaling and a paclitaxel-resistant phenotype. Int. J. Cancer 2008, 122:281-288.
57. Li J., Vesey D.A., Johnson D.W., Gobe G. Erythropoietin reduces cisplatin-induced apoptosis in renal carcinoma cells via a PKC dependent pathway. Cancer Biol. Ther. 2007, 6:1944-1950.
58. Semenza G.L. Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Crit. Rev. Biochem. Mol. Biol. 2000, 35:71-103.
59. Ebert B.L., Bunn H.F. Regulation of the erythropoietin gene. Blood 1999, 94:1864-1877.
60. Rankin E.B., Biju M.P., Liu Q., Unger T.L., Rha J., Johnson R.S., Simon M.C., Keith B., Haase V.H. Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo. J. Clin. Invest. 2007, 117:1068-1077.
61. Acs G., Zhang P.J., Rebbeck T.R., Acs P., Verma A. Immunohistochemical expression of erythropoietin and erythropoietin receptor in breast carcinoma. Cancer 2002, 95:969-981.
62. Acs G., Zhang P.J., McGrath C.M., Acs P., McBroom J., Mohyeldin A., Liu S., Lu H., Verma A. Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression. Am. J. Pathol. 2003, 162:1789-1806.
63. Constantinescu S.N., Keren T., Socolovsky M., Nam H., Henis Y.I., Lodish H.F. Ligand-independent oligomerization of cell-surface erythropoietin receptor is mediated by the transmembrane domain. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:4379-4384.
64. Brines M., Grasso G., Fiordaliso F., Sfacteria A., Ghezzi P., Fratelli M., Latini R., Xie Q., Smart J., Su-Rick C., Pobre E., Diaz D., Gomez D., Hand C., Coleman T., Cerami A. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:14907-14912.
65. Arcasoy M.O. The non-haematopoietic biological effects of erythropoietin. Br. J. Haematol. 2008, 141:14-31.
66. Um M., Gross A.W., Lodish H.F. A "classical" homodimeric erythropoietin receptor is essential for the antiapoptotic effects of erythropoietin on differentiated neuroblastoma SH-SY5Y and pheochromocytoma PC-12 cells. Cell. Signal. 2007, 19:634-645.
67. Sytkowski A.J. Does erythropoietin have a dark side? Epo signaling and cancer cells. Sci. STKE. 2007, 2007:e38.
68. McCaffery P.J., Fraser J.K., Lin F.K., Berridge M.V. Subunit structure of the erythropoietin receptor. J. Biol. Chem. 1989, 264:10507-10512.
69. Frank S.J. Receptor dimerization in GH and erythropoietin action-it takes two to tango, but how?. Endocrinology 2002, 143:2-10.
70. Richmond T.D., Chohan M., Barber D.L. Turning cells red: signal transduction mediated by erythropoietin. Trends Cell Biol. 2005, 15:146-155.
71. Boudot C., Petitfrère E., Kadri Z., Chretien S., Mayeux P., Haye B., Billat C. Erythropoietin induces glycosylphosphatidylinositol hydrolysis. Possible involvement of phospholipase c-gamma(2). J. Biol. Chem. 1999, 274:33966-33972.
72. Chen C., Sytkowski A.J. Erythropoietin activates two distinct signaling pathways required for the initiation and the elongation of c-myc. J. Biol. Chem. 2001, 276:38518-38526.
73. Silva M., Benito A., Sanz C., Prosper F., Ekhterae D., Nuñez G., Fernandez-Luna J.L. Erythropoietin can induce the expression of bcl-x(L) through Stat5 in erythropoietin-dependent progenitor cell lines. J. Biol. Chem. 1999, 274:22165-22169.
74. Tsushima H., Urata Y., Miyazaki Y., Fuchigami K., Kuriyama K., Kondo T., Tomonaga M. Human erythropoietin receptor increases GATA-2 and Bcl-xL by a protein kinase C-dependent pathway in human erythropoietin-dependent cell line AS-E2. Cell Growth Differ. 1997, 8:1317-1328.
75. Mori M., Uchida M., Watanabe T., Kirito K., Hatake K., Ozawa K., Komatsu N. Activation of extracellular signal-regulated kinases ERK1 and ERK2 induces Bcl-xL up-regulation via inhibition of caspase activities in erythropoietin signaling. J. Cell. Physiol. 2003, 195:290-297.
76. Zhang M.Y., Harhaj E.W., Bell L., Sun S.C., Miller B.A. Bcl-3 expression and nuclear translocation are induced by granulocyte-macrophage colony-stimulating factor and erythropoietin in proliferating human erythroid precursors. Blood 1998, 92:1225-1234.
77. Diehl J.A., Cheng M., Roussel M.F., Sherr C.J. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 1998, 12:3499-3511.
78. Li Y., Davis K.L., Sytkowski A.J. Protein kinase C-epsilon is necessary for erythropoietin's up-regulation of c-myc and for factor-dependent DNA synthesis. Evidence for discrete signals for growth and differentiation. J. Biol. Chem. 1996, 271:27025-27030.
79. Klingmüller U., Lorenz U., Cantley L.C., Neel B.G., Lodish H.F. Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals. Cell 1995, 80:729-738.
80. Cohen J., Oren-Young L., Klingmuller U., Neumann D. Protein tyrosine phosphatase 1B participates in the down-regulation of erythropoietin receptor signalling. Biochem. J. 2004, 377:517-524.
81. Kile B.T., Alexander W.S. The suppressors of cytokine signalling (SOCS). Cell. Mol. Life Sci. 2001, 58:1627-1635.
82. Jegalian A.G., Wu H. Differential roles of SOCS family members in EpoR signal transduction. J. Interferon. Cytokine Res. 2002, 22:853-860.
83. Walrafen P., Verdier F., Kadri Z., Chrétien S., Lacombe C., Mayeux P. Both proteasomes and lysosomes degrade the activated erythropoietin receptor. Blood 2005, 105:600-608.
84. Dunlop E.A., Maxwell A.P., Lappin T.R.J. Impaired downregulation following erythropoietin receptor activation in non-small cell lung carcinoma. Stem Cells. 2007, 25:380-384.
85. Dunlop E.A., Percy M.J., Boland M.P., Maxwell A.P., Lappin T.R. Induction of signalling in non-erythroid cells by pharmacological levels of erythropoietin. Neurodegener. Dis. 2006, 3:94-100.
86. Arcasoy M.O., Amin K., Chou S., Haroon Z.A., Varia M., Raleigh J.A. Erythropoietin and erythropoietin receptor expression in head and neck cancer: relationship to tumor hypoxia. Clin. Cancer Res. 2005, 11:20-27.
87. Arcasoy M.O., Amin K., Karayal A.F., Chou S., Raleigh J.A., Varia M.A., Haroon Z.A. Functional significance of erythropoietin receptor expression in breast cancer. Lab. Invest. 2002, 82:911-918.
88. Arcasoy M.O., Amin K., Vollmer R.T., Jiang X., Demark-Wahnefried W., Haroon Z.A. Erythropoietin and erythropoietin receptor expression in human prostate cancer. Mod. Pathol. 2005, 18:421-430.
89. Ribatti D., Marzullo A., Nico B., Crivellato E., Ria R., Vacca A. Erythropoietin as an angiogenic factor in gastric carcinoma. Histopathology 2003, 42:246-250.
90. Arcasoy M.O., Jiang X., Haroon Z.A. Expression of erythropoietin receptor splice variants in human cancer. Biochem. Biophys. Res. Commun. 2003, 307:999-1007.
91. Selzer E., Wacheck V., Kodym R., Schlagbauer-Wadl H., Schlegel W., Pehamberger H., Jansen B. Erythropoietin receptor expression in human melanoma cells. Melanoma Res. 2000, 10:421-426.
92. Mirmohammadsadegh A., Marini A., Gustrau A., Delia D., Nambiar S., Hassan M., Hengge U.R. Role of erythropoietin receptor expression in malignant melanoma. J. Invest. Dermatol. 2010, 130:201-210.
93. McBroom J.W., Acs G., Rose G.S., Krivak T.C., Mohyeldin A., Verma A. Erythropoietin receptor function and expression in epithelial ovarian carcinoma. Gynecol. Oncol. 2005, 99:571-577.
94. Saintigny P., Besse B., Callard P., Vergnaud A., Czernichow S., Colombat M., Girard P., Validire P., Breau J., Bernaudin J., Soria J. Erythropoietin and erythropoietin receptor coexpression is associated with poor survival in stage I non-small cell lung cancer. Clin. Cancer Res. 2007, 13:4825-4831.
95. Larsson A., Jirström K., Fredlund E., Nilsson S., Rydén L., Landberg G., Påhlman S. Erythropoietin receptor expression and correlation to tamoxifen response and prognosis in breast cancer. Clin. Cancer Res. 2009, 15:5552-5559.
96. Jeong J., Hoxhaj G., Socha A.L., Sytkowski A.J., Feldman L. An erythropoietin autocrine/paracrine axis modulates the growth and survival of human prostate cancer cells. Mol. Cancer Res. 2009, 7:1150-1157.
97. Lai S.Y., Childs E.E., Xi S., Coppelli F.M., Gooding W.E., Wells A., Ferris R.L., Grandis J.R. Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma. Oncogene 2005, 24:4442-4449.
98. Gewirtz D.A., Di X., Walker T.D., Sawyer S.T. Erythropoietin fails to interfere with the antiproliferative and cytotoxic effects of antitumor drugs. Clin. Cancer Res. 2006, 12:2232-2238.
99. Liu W.M., Powles T., Shamash J., Propper D., Oliver T., Joel S. Effect of haemopoietic growth factors on cancer cell lines and their role in chemosensitivity. Oncogene 2004, 23:981-990.
100. Laugsch M., Metzen E., Svensson T., Depping R., Jelkmann W. Lack of functional erythropoietin receptors of cancer cell lines. Int. J. Cancer 2008, 122:1005-1011.
101. Jeong J., Feldman L., Solar P., Szenajch J., Sytkowski A.J. Characterization of erythropoietin receptor and erythropoietin expression and function in human ovarian cancer cells. Int. J. Cancer. 2008, 122:274-280.
102. Paragh G., Kumar S.M., Rakosy Z., Choi S., Xu X., Acs G. RNA interference-mediated inhibition of erythropoietin receptor expression suppresses tumor growth and invasiveness in A2780 human ovarian carcinoma cells. Am. J. Pathol. 2009, 174:1504-1514.
103. LaMontagne K.R., Butler J., Marshall D.J., Tullai J., Gechtman Z., Hall C., Meshaw A., Farrell F.X. Recombinant epoetins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models. Mol. Cancer Ther. 2006, 5:347-355.
104. McMahon F.G., Vargas R., Ryan M., Jain A.K., Abels R.I., Perry B., Smith I.L. Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers. Blood 1990, 76:1718-1722.
105. Jelkmann W. Pharmacology, pharmacokinetics and safety of recombinant human preparations. Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology 2008, 407-431. Springer, Wien New York. M. Noworousian (Ed.).
106. Lester R.D., Jo M., Campana W.M., Gonias S.L. Erythropoietin promotes MCF-7 breast cancer cell migration by an ERK/mitogen-activated protein kinase-dependent pathway and is primarily responsible for the increase in migration observed in hypoxia. J. Biol. Chem. 2005, 280:39273-39277.
107. Mohyeldin A., Lu H., Dalgard C., Lai S.Y., Cohen N., Acs G., Verma A. Erythropoietin signaling promotes invasiveness of human head and neck squamous cell carcinoma. Neoplasia 2005, 7:537-543.
108. Brown W.M., Maxwell P., Graham A.N.J., Yakkundi A., Dunlop E.A., Shi Z., Johnston P.G., Lappin T.R.J. Erythropoietin receptor expression in non-small cell lung carcinoma: a question of antibody specificity. Stem Cells 2007, 25:718-722.
109. Elliott S., Busse L., McCaffery I., Rossi J., Sinclair A., Spahr C., Swift S., Begley C.G. Identification of a sensitive anti-erythropoietin receptor monoclonal antibody allows detection of low levels of EpoR in cells. J. Immunol. Methods 2010, 352:126-139.
110. Yet M.G., Jones S.S. The extracytoplasmic domain of the erythropoietin receptor forms a monomeric complex with erythropoietin. Blood 1993, 82:1713-1719.
111. Kelleher D., Thews O., Vaupel P. Modulation of tumor oxygenation and radiosensitivity by erythropoietin. Tumor Hypoxia 1999, 83-90. Wissenschaftlische Verlagsgessellschaft, Stuttgart. P. Vaupel, D. Kelleher (Eds.).
112. Silver D.F., Piver M.S. Effects of recombinant human erythropoietin on the antitumor effect of cisplatin in SCID mice bearing human ovarian cancer: a possible oxygen effect. Gynecol. Oncol. 1999, 73:280-284.
113. Thews O., Kelleher D.K., Vaupel P. Erythropoietin restores the anemia-induced reduction in cyclophosphamide cytotoxicity in rat tumors. Cancer Res. 2001, 61:1358-1361.
114. Stüben G., Pöttgen C., Knühmann K., Schmidt K., Stuschke M., Thews O., Vaupel P. Erythropoietin restores the anemia-induced reduction in radiosensitivity of experimental human tumors in nude mice. Int. J. Radiat. Oncol. Biol. Phys. 2003, 55:1358-1362.
115. Henke M., Guttenberger R., Barke A., Pajonk F., Pötter R., Frommhold H. Erythropoietin for patients undergoing radiotherapy: a pilot study. Radiother. Oncol. 1999, 50:185-190.
116. Lavey R. Clinical trial experience using erythropoietin during radiation therapy. Tumor Hypoxia 1999, 99-105. Wissenschaftlische Verlagsgessellschaft, Stuttgart. P. Vaupel, D. Kelleher (Eds.).
117. Glaser C.M., Millesi W., Kornek G.V., Lang S., Schüll B., Watzinger F., Selzer E., Lavey R.S. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int. J. Radiat. Oncol. Biol. Phys. 2001, 50:705-715.
118. Vaupel P., Thews O., Hoeckel M. Treatment resistance of solid tumors: role of hypoxia and anemia. Med. Oncol. 2001, 18:243-259.
119. Kumar P. Impact of anemia in patients with head and neck cancer. Oncologist 2000, 5(Suppl 2):13-18.
120. Anagnostou A., Lee E.S., Kessimian N., Levinson R., Steiner M. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc. Natl. Acad. Sci. U. S. A. 1990, 87:5978-5982.
121. Anagnostou A., Liu Z., Steiner M., Chin K., Lee E.S., Kessimian N., Noguchi C.T. Erythropoietin receptor mRNA expression in human endothelial cells. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:3974-3978.
122. Hadland B.K., Longmore G.D. Erythroid-stimulating agents in cancer therapy: potential dangers and biologic mechanisms. J. Clin. Oncol. 2009, 27:4217-4226.
123. Connell P.P., Martel M.K., Hellman S. Principles of Radiation Oncology. Principles and Practice of Oncology 2005, 267-293. Lippincott Williams and Wilkins, Philadelphia. V.T. DeVita, S. Hellman, S.A. Rosenberg (Eds.).
124. Johnson S.W., O'Dwyer P.J. Pharmacology of cancer chemotherapy: cisplatin and its analogues. Principles and Practice of Oncology 2005, 344-358. Lippincott Williams and Wilkins, Philadelphia. V.T. DeVita, S. Hellman, S.A. Rosenberg (Eds.).
125. Takimoto C.H. Pharmacology of cancer chemotherapy: topoisomerase interactive agents. Principles and Practice of Oncology 2005, 375-388. Lippincott Williams and Wilkins, Philadelphia. V.T. DeVita, S. Hellman, S.A. Rosenberg (Eds.).
126. Colvin O.M., Friedman H.S. Pharmacology of cancer chemotherapy: alkylating agents. Principles and Practice of Oncology 2005, 332-344. Lippincott Williams and Wilkins, Philadelphia. V.T. DeVita, S. Hellman, S.A. Rosenberg (Eds.).
127. Rowinsky E.K., Tolcher A.W. Pharmacology of cancer chemotherapy: antimicrotubule agents. Principles and Practice of Oncology 2005, 390-416. Lippincott Williams and Wilkins, Philadelphia. V.T. DeVita, S. Hellman, S.A. Rosenberg (Eds.).
128. Goetz M.P., Erlichman C., Loprinzi C.L. Pharmacology of Endocrine Manipulation. Principles and Practice of Oncology 2005, 457-469. Lippincott Williams and Wilkins, Philadelphia. 7th ed. V.T. DeVita, S. Hellman, S.A. Rosenberg (Eds.).
129. Agostinis P., Buytaert E., Breyssens H., Hendrickx N. Regulatory pathways in photodynamic therapy induced apoptosis. Photochem. Photobiol. Sci. 2004, 3:721-729.
130. Buytaert E., Dewaele M., Agostinis P. Molecular effectors of multiple cell death pathways initiated by photodynamic therapy. Biochim. Biophys. Acta 2007, 1776:86-107.
131. Belenkov A.I., Shenouda G., Rizhevskaya E., Cournoyer D., Belzile J., Souhami L., Devic S., Chow T.Y.K. Erythropoietin induces cancer cell resistance to ionizing radiation and to cisplatin. Mol. Cancer Ther. 2004, 3:1525-1532.
132. Pajonk F., Weil A., Sommer A., Suwinski R., Henke M. The erythropoietin-receptor pathway modulates survival of cancer cells. Oncogene 2004, 23:8987-8991.
133. Solár P., Koval J., Mikes J., Kleban J., Solárová Z., Lazúr J., Hodorová I., Fedorocko P., Sytkowski A.J. Erythropoietin inhibits apoptosis induced by photodynamic therapy in ovarian cancer cells. Mol. Cancer Ther. 2008, 7:2263-2271.
134. Dent P., Yacoub A., Fisher P.B., Hagan M.P., Grant S. MAPK pathways in radiation responses. Oncogene. 2003, 22:5885-5896.
135. Dent P., Grant S. Pharmacologic interruption of the mitogen-activated extracellular-regulated kinase/mitogen-activated protein kinase signal transduction pathway: potential role in promoting cytotoxic drug action. Clin. Cancer Res. 2001, 7:775-783.
136. Dent P., Yacoub A., Contessa J., Caron R., Amorino G., Valerie K., Hagan M.P., Grant S., Schmidt-Ullrich R. Stress and radiation-induced activation of multiple intracellular signaling pathways. Radiat. Res. 2003, 159:283-300.
137. Siddik Z.H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003, 22:7265-7279.
138. McCubrey J.A., Steelman L.S., Chappell W.H., Abrams S.L., Wong E.W.T., Chang F., Lehmann B., Terrian D.M., Milella M., Tafuri A., Stivala F., Libra M., Basecke J., Evangelisti C., Martelli A.M., Franklin R.A. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim. Biophys. Acta 2007, 1773:1263-1284.
139. Blagosklonny M.V., Fojo T. Molecular effects of paclitaxel: myths and reality (a critical review). Int. J. Cancer 1999, 83:151-156.
140. Estève M., Carré M., Braguer D. Microtubules in apoptosis induction: are they necessary?. Curr. Cancer Drug Targets 2007, 7:713-729.
141. Ferlini C., Raspaglio G., Mozzetti S., Distefano M., Filippetti F., Martinelli E., Ferrandina G., Gallo D., Ranelletti F.O., Scambia G. Bcl-2 down-regulation is a novel mechanism of paclitaxel resistance. Mol. Pharmacol. 2003, 64:51-58.
142. Royds J.A., Dower S.K., Qwarnstrom E.E., Lewis C.E. Response of tumour cells to hypoxia: role of p53 and NFkB, MP. Mol. Pathol. 1998, 51:55-61.
143. Tang J., Kawadler H., Yang X. Lymphocyte life and death: the caspase-8 connection. Cancer Biol. Ther. 2005, 4:700-702.
144. Thome M., Weil R. Post-translational modifications regulate distinct functions of CARMA1 and BCL10. Trends Immunol. 2007, 28:281-288.